金活醫藥集團(01110.HK)年度純利增加158.8%至3031.9萬元 末期息2.39港仙
格隆匯3月29日丨金活醫藥集團(01110.HK)發佈年度業績公吿,2021年收益增加13.7%至約人民幣8.474億元;毛利減少5.9%至約人民幣2.636億元;公司擁有人應占溢利增加158.8%至約人民幣3031.9萬元;每股基本盈利約人民幣5.00分;董事會建議派發末期股息每股2.39港仙。
回顧年度內,集團的收益同比13.7%。此項增加主要原因為京都念慈庵蜜煉川貝枇杷膏的收益增加所致。該項增加主要原因為疫情防控及對疫情有更好的瞭解,使市場需求在回顧年度期間相對2020年度趨向復甦而有所增加所致。惟部分給東迪欣生產的醫療設備產品,包括紅外線測温儀,銷售減少所抵銷。此類防疫產品於2020年度內需求很大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.